NIKKEI 225
27,327.11 -106.29 (-0.39%) HANG SENG
21,842.33 -227.40 (-1.03%) CRUDE OIL
79.12 +1.22 (+1.57%) GOLD FUTURES
1,943.80 +4.60 (+0.24%) DOW
34,086.04 +368.95 (+1.09%) BTC-GBP
18,620.84 +39.76 (+0.21%)
CytomX Therapeutics, Inc. (CTMX)
After hours:
| Previous close | 2.6800 |
| Open | 2.6300 |
| Bid | 2.6500 x 4000 |
| Ask | 2.7400 x 3200 |
| Day's range | 2.6300 - 2.7350 |
| 52-week range | 1.1700 - 4.7300 |
| Volume | |
| Avg. volume | 3,205,898 |
| Market cap | 178.428M |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4090 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.82 |
- Simply Wall St.
An Intrinsic Calculation For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Suggests It's 38% Undervalued
Does the January share price for CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) reflect what it's really worth? Today, we...
- Zacks
CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.
- Reuters
Moderna signs $35 million deal with cancer drug developer CytomX
The news comes a month after an experimental cancer vaccine from Moderna based on mRNA technology was shown to work against a type of skin cancer. The deal offers CytomX access to Moderna's mRNA technology, which has been used to develop COVID-19 vaccines, while Moderna would get access to CytomX's Probody platform, used in the development of cancer therapies targeting diseased tissues. Moderna said it will also pay tiered royalties to CytomX on global sales of any products which enter the market under the deal.
